Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AUDIOEYE INCAEYE · Entity 6844 | Director | October 01, 2026 | October 03, 2026 |
| IRADIMED CORPIRMD · Entity 4896 | Director | December 11, 2025 | December 15, 2025 |
| NATUS MEDICAL INCBABY · Entity 125256 | Director · President and CEO | April 30, 2018 | May 02, 2018 |
| OSI SYSTEMS INCOSIS · Entity 4160 | Director | August 20, 2026 | August 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AUDIOEYE INC
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 218,684 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 1,000 · Balance 218,684 F1: The securities relate to a quarterly grant of shares of common stock under the AudioEye, Inc. 2020 Equity Incentive Plan, which shares were fully vested on the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities relate to a quarterly grant of shares of common stock under the AudioEye, Inc. 2020 Equity Incentive Plan, which shares were fully vested on the grant date.
IRADIMED CORP
Report date December 11, 2025 · Filed December 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,932 |
Reported balance
After 2025-12-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-11 · Grant · Acquired 1,026 · Balance 1,932 F1: Restricted stock units convert into common stock on a one-for-one basis. F2: On December 11, 2025, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 11, 2026. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: On December 11, 2025, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 11, 2026. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.
NATUS MEDICAL INC
Report date April 30, 2018 · Filed May 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par value per shareSEC Table I · non-derivative | Direct | 639,257 |
Ending reported balance
After 2018-04-30 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2018-04-30 · Exercise / conversion · Acquired 47,500 · Balance 686,757 Row 2 · 2018-04-30 · Sale · Disposed 47,500 · Balance 639,257 F1: This transaction was executed in multiple trades at prices ranging from $32.90 to $34.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2018-04-30 · Exercise / conversion · Acquired 76,827 · Balance 716,084 Row 4 · 2018-04-30 · Sale · Disposed 76,827 · Balance 639,257 F2: This transaction was executed in multiple trades at prices ranging from $33.05 to $33.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 5 · 2018-04-30 · Exercise / conversion · Acquired 35,673 · Balance 674,930 Row 6 · 2018-04-30 · Sale · Disposed 35,673 · Balance 639,257 F3: This transaction was executed in multiple trades at prices ranging from $32.65 to $33.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Nonqualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $10.69 · Expires 2018-06-07 | Direct | 112,500 |
Reported balance
After 2018-04-30 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-04-30 · Exercise / conversion · Disposed 47,500 · Balance 112,500 |
| Nonqualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $10.69 · Expires 2018-06-07 | Direct | 35,673 |
Reported balance
After 2018-05-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-05-01 · Exercise / conversion · Disposed 76,827 · Balance 35,673 |
| Nonqualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $10.69 · Expires 2018-06-07 | Direct | 0 |
Reported balance
After 2018-05-02 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-05-02 · Exercise / conversion · Disposed 35,673 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $32.90 to $34.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: This transaction was executed in multiple trades at prices ranging from $33.05 to $33.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $32.65 to $33.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
OSI SYSTEMS INC
Report date August 20, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,295 |
Reported balance
After 2026-08-20 transaction · row 1
1 source rowRow 1 · 2026-08-20 · Tax withholding · Disposed 90 · Balance 5,295 F1: Pursuant with a net settlement, shares of stock were tendered to pay for the tax withholding. No shares of stock were sold. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant with a net settlement, shares of stock were tendered to pay for the tax withholding. No shares of stock were sold.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Caesars Entertainment, Inc.
Report date July 20, 2020 · Filed July 23, 2020
Section 16 reporting ended · disclosed 2020-07-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 128,082 |
Ending reported balance
After 2020-07-20 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2020-07-20 · Exercise / conversion · Acquired 9,256 · Balance 91,256 F1: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with Eldorado Resorts, Inc. (n/k/a Caesars Entertainment, Inc., the "Company"), all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. Row 2 · 2020-07-20 · Exercise / conversion · Acquired 17,980 · Balance 109,236 F2: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. Row 3 · 2020-07-20 · Exercise / conversion · Acquired 6,984 · Balance 116,220 F3: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. Row 4 · 2020-07-20 · Exercise / conversion · Acquired 4,612 · Balance 120,832 F4: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. Row 5 · 2020-07-20 · Exercise / conversion · Acquired 4,305 · Balance 125,137 F5: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. Row 6 · 2020-07-20 · Exercise / conversion · Acquired 2,945 · Balance 128,082 F6: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2020-07-20 | Direct | 0 |
Reported balance
After 2020-07-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-07-20 · Exercise / conversion · Disposed 9,256 · Balance 0 F1: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with Eldorado Resorts, Inc. (n/k/a Caesars Entertainment, Inc., the "Company"), all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2020-07-20 | Direct | 0 |
Reported balance
After 2020-07-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-07-20 · Exercise / conversion · Disposed 17,980 · Balance 0 F2: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2020-07-20 | Direct | 0 |
Reported balance
After 2020-07-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-07-20 · Exercise / conversion · Disposed 6,984 · Balance 0 F3: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2020-07-20 | Direct | 0 |
Reported balance
After 2020-07-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-07-20 · Exercise / conversion · Disposed 4,612 · Balance 0 F4: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2020-07-20 | Direct | 0 |
Reported balance
After 2020-07-20 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-07-20 · Exercise / conversion · Disposed 4,305 · Balance 0 F5: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2020-07-20 | Direct | 0 |
Reported balance
After 2020-07-20 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2020-07-20 · Exercise / conversion · Disposed 2,945 · Balance 0 F6: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with Eldorado Resorts, Inc. (n/k/a Caesars Entertainment, Inc., the "Company"), all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock.
F2: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock.
F3: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock.
F4: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock.
F5: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock.
F6: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 01, 2023 Filed Dec 5, 2023 21:30 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionStock Options (Right to Buy) · Derivative | 5,259 | $0.00 Strike: $7.10 | $0.00 |
DisclosureSEC source: 0001415889-23-015865 · form4-12052023_041221.xml · derivative · entry 5 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,741 Underlying: Common Stock · 5,259 shares Expires 2024-09-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option, representing a right to purchase a total of 10,000 shares, was granted on 9-29-2014 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:30 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,259 | $43.28 | $227,593.22 |
DisclosureSEC source: 0001415889-23-015865 · form4-12052023_041221.xml · nonDerivative · entry 2 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,562 F2 · price: This transaction was executed in multiple trades at prices ranging from $42.70 to $43.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:30 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 5,259 | $7.10 | $37,338.90 |
DisclosureSEC source: 0001415889-23-015865 · form4-12052023_041221.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,821 F1 · price: This option, representing a right to purchase a total of 10,000 shares, was granted on 9-29-2014 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| July 28, 2023 Filed Aug 2, 2023 01:41 UTC | OSI SYSTEMS INC OSIS · Entity 4160 | GrantCommon Stock | 1,700 | $117.63 | $199,971.00 |
DisclosureSEC source: 0001415889-23-011694 · form4-08022023_010843.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,834 Read SEC document |
| July 10, 2023 Filed Jul 12, 2023 01:50 UTC | OSI SYSTEMS INC OSIS · Entity 4160 | Tax withholdingCommon Stock | 476 | $113.37 | $53,964.12 |
DisclosureSEC source: 0001415889-23-011038 · form4-07112023_090701.xml · nonDerivative · entry 2 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,134 F1 · shares: Pursuant with a net settlement, shares of stock were tendered to pay for the tax withholding. No shares of stock were sold. Read SEC document |
| July 06, 2023 Filed Jul 12, 2023 01:50 UTC | OSI SYSTEMS INC OSIS · Entity 4160 | Tax withholdingCommon Stock | 230 | $115.52 | $26,569.60 |
DisclosureSEC source: 0001415889-23-011038 · form4-07112023_090701.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,610 F1 · shares: Pursuant with a net settlement, shares of stock were tendered to pay for the tax withholding. No shares of stock were sold. Read SEC document |
| February 09, 2023 Filed Feb 9, 2023 21:01 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 2,000 | $35.60 | $71,200.00 |
DisclosureSEC source: 0000898432-23-000063 · form4.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,562 F1 · price: This transaction was executed in multiple trades all at $35.60. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 13, 2022 Filed Apr 4, 2023 20:47 UTC | OSI SYSTEMS INC OSIS · Entity 4160 | GrantCommon Stock | 148 | $84.79 | $12,548.92 |
DisclosureSEC source: 0001415889-23-006054 · form4-04042023_080413.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,840 Read SEC document |
| December 07, 2022 Filed Dec 8, 2022 23:20 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantRestricted Stock Units · Derivative | 3,501 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-22-000658 · form4.xml · derivative · entry 5 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,537 Underlying: Common Stock · 3,501 shares Expires not disclosed F1 · derivative.exercise_price: Restricted Stock Units convert to common stock on a one-for-one basis. F4 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F4 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 07, 2022 Filed Dec 8, 2022 23:20 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionRestricted Stock Units · Derivative | 1,035 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-22-000658 · form4.xml · derivative · entry 4 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,036 Underlying: Common Stock · 1,035 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units convert to common stock on a one-for-one basis. F3 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2022. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F3 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2022. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 07, 2022 Filed Dec 8, 2022 23:20 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionRestricted Stock Units · Derivative | 2,037 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-22-000658 · form4.xml · derivative · entry 3 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,037 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units convert to common stock on a one-for-one basis. F2 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2021. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2021. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 07, 2022 Filed Dec 8, 2022 23:20 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionCommon Stock | 1,035 | $28.56 | $29,559.60 |
DisclosureSEC source: 0000898432-22-000658 · form4.xml · nonDerivative · entry 2 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2022 Filed Dec 8, 2022 23:20 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionCommon Stock | 2,037 | $28.56 | $58,176.72 |
DisclosureSEC source: 0000898432-22-000658 · form4.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,527 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2022 Filed Dec 8, 2022 17:33 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 5,000 | $28.58 | $142,905.50 |
DisclosureSEC source: 0000898432-22-000656 · form4.xml · nonDerivative · entry 2 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,490 F2 · price: This transaction was executed in multiple trades at prices ranging from $28.48 to $28.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 06, 2022 Filed Dec 8, 2022 17:33 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 5,000 | $28.55 | $142,727.50 |
DisclosureSEC source: 0000898432-22-000656 · form4.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,490 F1 · price: This transaction was executed in multiple trades at prices ranging from $28.45 to $28.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 20:38 UTC | OSI SYSTEMS INC OSIS · Entity 4160 | GrantCommon Stock | 2,302 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-007590 · form4-07082022_010720.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,692 Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 22:05 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionStock Options (Right to Buy) · Derivative | 9,441 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0000898432-22-000119 · form4.xml · derivative · entry 3 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,441 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 22:05 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 9,441 | $50.22 | $474,145.90 |
DisclosureSEC source: 0000898432-22-000119 · form4.xml · nonDerivative · entry 2 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,490 F2 · price: This transaction was executed in multiple trades at prices ranging from $50.20 to $50.34. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 22:05 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 9,441 | $1.48 | $13,972.68 |
DisclosureSEC source: 0000898432-22-000119 · form4.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,931 F1 · price: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 02:40 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionStock Options (Right to Buy) · Derivative | 559 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0000898432-21-000772 · form4.xml · derivative · entry 9 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,441 Underlying: Common Stock · 559 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 02:40 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 559 | $48.50 | $27,111.50 |
DisclosureSEC source: 0000898432-21-000772 · form4.xml · nonDerivative · entry 5 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,490 Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 02:40 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 559 | $1.48 | $827.32 |
DisclosureSEC source: 0000898432-21-000772 · form4.xml · nonDerivative · entry 4 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,049 F1 · price: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 02:40 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantRestricted Stock Units · Derivative | 2,071 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-21-000772 · form4.xml · derivative · entry 8 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,071 Underlying: Common Stock · 2,071 shares Expires not disclosed F4 · derivative.exercise_price: Restricted Stock Units convert to common stock on a one-for-one basis. F5 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2022. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F5 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2022. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 02:40 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionRestricted Stock Units · Derivative | 4,222 | $0.00 | $0.00 |
DisclosureSEC source: 0000898432-21-000772 · form4.xml · derivative · entry 7 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,037 Underlying: Common Stock · 4,222 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Restricted Stock Units convert to common stock on a one-for-one basis. F3 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2020 and 2021. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F3 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2020 and 2021. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 02:40 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionStock Options (Right to Buy) · Derivative | 18,743 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0000898432-21-000772 · form4.xml · derivative · entry 6 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 18,743 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 02:40 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionCommon Stock | 4,222 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-21-000772 · form4.xml · nonDerivative · entry 3 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2020 and 2021. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 02:40 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 18,743 | $47.07 | $882,289.24 |
DisclosureSEC source: 0000898432-21-000772 · form4.xml · nonDerivative · entry 2 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,268 F2 · price: This transaction was executed in multiple trades at prices ranging from $46.30 to $48.54. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 02:40 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 18,743 | $1.48 | $27,739.64 |
DisclosureSEC source: 0000898432-21-000772 · form4.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,011 F1 · price: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| November 30, 2021 Filed Nov 30, 2021 23:45 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionStock Options (Right to Buy) · Derivative | 1,257 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0000898432-21-000745 · form4.xml · derivative · entry 9 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,743 Underlying: Common Stock · 1,257 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| November 30, 2021 Filed Nov 30, 2021 23:45 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 1,257 | $46.23 | $58,112.24 |
DisclosureSEC source: 0000898432-21-000745 · form4.xml · nonDerivative · entry 6 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,268 F3 · price: This transaction was executed in multiple trades at prices ranging from $46.20 to $46.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 30, 2021 Filed Nov 30, 2021 23:45 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 1,257 | $1.48 | $1,860.36 |
DisclosureSEC source: 0000898432-21-000745 · form4.xml · nonDerivative · entry 5 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,525 F1 · price: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| November 29, 2021 Filed Nov 30, 2021 23:45 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionStock Options (Right to Buy) · Derivative | 12,176 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0000898432-21-000745 · form4.xml · derivative · entry 8 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 12,176 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| November 29, 2021 Filed Nov 30, 2021 23:45 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 12,176 | $46.11 | $561,435.36 |
DisclosureSEC source: 0000898432-21-000745 · form4.xml · nonDerivative · entry 4 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,268 F2 · price: This transaction was executed in multiple trades at prices ranging from $44.44 to $46.86. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 29, 2021 Filed Nov 30, 2021 23:45 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 12,176 | $1.48 | $18,020.48 |
DisclosureSEC source: 0000898432-21-000745 · form4.xml · nonDerivative · entry 3 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,444 F1 · price: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 23:45 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionStock Options (Right to Buy) · Derivative | 4,332 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0000898432-21-000745 · form4.xml · derivative · entry 7 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,176 Underlying: Common Stock · 4,332 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 23:45 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 4,332 | $44.00 | $190,608.00 |
DisclosureSEC source: 0000898432-21-000745 · form4.xml · nonDerivative · entry 2 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,268 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 23:45 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 4,332 | $1.48 | $6,411.36 |
DisclosureSEC source: 0000898432-21-000745 · form4.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,600 F1 · price: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| November 24, 2021 Filed Nov 24, 2021 23:34 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionStock Options (Right to Buy) · Derivative | 37,454 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0000898432-21-000740 · form4.xml · derivative · entry 6 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,508 Underlying: Common Stock · 37,454 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| November 24, 2021 Filed Nov 24, 2021 23:34 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 37,454 | $42.95 | $1,608,746.68 |
DisclosureSEC source: 0000898432-21-000740 · form4.xml · nonDerivative · entry 4 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,268 F3 · price: This transaction was executed in multiple trades at prices ranging from $42.25 to $44.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 24, 2021 Filed Nov 24, 2021 23:34 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 37,454 | $1.48 | $55,431.92 |
DisclosureSEC source: 0000898432-21-000740 · form4.xml · nonDerivative · entry 3 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,722 F1 · price: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| November 23, 2021 Filed Nov 24, 2021 23:34 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionStock Options (Right to Buy) · Derivative | 6,038 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0000898432-21-000740 · form4.xml · derivative · entry 5 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,962 Underlying: Common Stock · 6,038 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| November 23, 2021 Filed Nov 24, 2021 23:34 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 6,038 | $41.20 | $248,780.70 |
DisclosureSEC source: 0000898432-21-000740 · form4.xml · nonDerivative · entry 2 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,268 F2 · price: This transaction was executed in multiple trades at prices ranging from $41.20 to $41.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 23, 2021 Filed Nov 24, 2021 23:34 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 6,038 | $1.48 | $8,936.24 |
DisclosureSEC source: 0000898432-21-000740 · form4.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,306 F1 · price: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| November 09, 2021 Filed Nov 10, 2021 22:09 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionStock Options (Right to Buy) · Derivative | 1,234 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0000898432-21-000723 · form4.xml · derivative · entry 9 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 1,234 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| November 09, 2021 Filed Nov 10, 2021 22:09 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 1,234 | $37.75 | $46,583.62 |
DisclosureSEC source: 0000898432-21-000723 · form4.xml · nonDerivative · entry 6 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,268 Read SEC document |
| November 09, 2021 Filed Nov 10, 2021 22:09 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 1,234 | $1.48 | $1,826.32 |
DisclosureSEC source: 0000898432-21-000723 · form4.xml · nonDerivative · entry 5 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,502 F1 · price: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| November 08, 2021 Filed Nov 10, 2021 22:09 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionStock Options (Right to Buy) · Derivative | 9,479 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0000898432-21-000723 · form4.xml · derivative · entry 8 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,234 Underlying: Common Stock · 9,479 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| November 08, 2021 Filed Nov 10, 2021 22:09 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 9,479 | $38.98 | $369,499.95 |
DisclosureSEC source: 0000898432-21-000723 · form4.xml · nonDerivative · entry 4 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,268 F3 · price: This transaction was executed in multiple trades at prices ranging from $38.60 to $39.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 08, 2021 Filed Nov 10, 2021 22:09 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 9,479 | $1.48 | $14,028.92 |
DisclosureSEC source: 0000898432-21-000723 · form4.xml · nonDerivative · entry 3 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,747 F1 · price: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| November 05, 2021 Filed Nov 10, 2021 22:09 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionStock Options (Right to Buy) · Derivative | 5,501 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0000898432-21-000723 · form4.xml · derivative · entry 7 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,713 Underlying: Common Stock · 5,501 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.